| scholarly article | Q13442814 |
| P50 | author | Alma Zernecke | Q21253006 |
| Christian Weber | Q37838769 | ||
| P2093 | author name string | Esther Lutgens | |
| Andrew C Newby | |||
| Dirk Lievens | |||
| Erwin Wijnands | |||
| Linda Beckers | |||
| Mat J A P Daemen | |||
| Randolph J Noelle | |||
| Cory L Ahonen | |||
| Jack Cleutjens | |||
| Ben J Janssen | |||
| Ulrike Benbow | |||
| Marjo M P C Donners | |||
| Johan Heemskerk | |||
| Imke Munnix | |||
| P2860 | cites work | CD40 AND CD154 IN CELL-MEDIATED IMMUNITY | Q22255634 |
| Reduction of atherosclerosis in mice by inhibition of CD40 signalling | Q24316540 | ||
| The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells | Q33711057 | ||
| TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs | Q33864629 | ||
| CD40 signaling and plaque instability | Q34460843 | ||
| Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype | Q35161070 | ||
| Inflammation and restenosis: implications for therapy. | Q35597634 | ||
| The in vivo function of a noncanonical TRAF2-binding domain in the C-terminus of CD40 in driving B-cell growth and differentiation | Q35850668 | ||
| CD40 and its ligand in atherosclerosis. | Q36812081 | ||
| CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis | Q37696199 | ||
| TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. | Q40474225 | ||
| CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site | Q40636873 | ||
| CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization | Q42060069 | ||
| Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation | Q42092461 | ||
| TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. | Q42509065 | ||
| Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus | Q43874081 | ||
| CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis. | Q44362136 | ||
| Absence of CD40 signaling is associated with an increase in intimal thickening after arterial injury | Q46113707 | ||
| Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. | Q46485545 | ||
| The glycoprotein VI-phospholipase Cgamma2 signaling pathway controls thrombus formation induced by collagen and tissue factor in vitro and in vivo | Q46778214 | ||
| CD40-mediated activation of vascular smooth muscle cell chemokine production through a Src-initiated, MAPK-dependent pathway | Q47306585 | ||
| Short-term and long-term blood pressure and heart rate variability in the mouse. | Q51421834 | ||
| Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? | Q52527039 | ||
| Requirement for CD154 in the progression of atherosclerosis. | Q52536870 | ||
| Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model | Q73265468 | ||
| Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow | Q73832982 | ||
| Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes | Q77658697 | ||
| Flow-induced vascular remodeling in the mouse: a model for carotid intima-media thickening | Q79202824 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4596-4604 | |
| P577 | publication date | 2008-01-14 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling | |
| P478 | volume | 111 |
| Q36662416 | Ambient particulate matter and microRNAs in extracellular vesicles: a pilot study of older individuals |
| Q38972708 | Blockade of CD40-TRAF2,3 or CD40-TRAF6 is sufficient to inhibit pro-inflammatory responses in non-haematopoietic cells |
| Q51035537 | Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice. |
| Q37599837 | Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance |
| Q26752784 | CD40 in coronary artery disease: a matter of macrophages? |
| Q34005419 | CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury |
| Q33732210 | CD40 signaling to the rescue: A CD8 exhaustion perspective in chronic infectious diseases |
| Q35879683 | CD40-TRAF Signaling Upregulates CX3CL1 and TNF-α in Human Aortic Endothelial Cells but Not in Retinal Endothelial Cells |
| Q33814059 | CD40L and Its Receptors in Atherothrombosis-An Update |
| Q46991200 | CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction |
| Q46284193 | CD40L controls obesity-associated vascular inflammation, oxidative stress and endothelial dysfunction in mice - translational aspects for man. |
| Q36903682 | Caveolin-1 deficiency decreases atherosclerosis by hampering leukocyte influx into the arterial wall and generating a regulatory T-cell response |
| Q36513984 | Circulating inflammatory cells are associated with vein graft stenosis |
| Q33816471 | Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients |
| Q35621648 | Crucial role of CD40 signaling in vascular wall cells in neointimal formation and vascular remodeling after vascular interventions |
| Q33656103 | Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile |
| Q41497361 | Distinct Differences on Neointima Formation in Immunodeficient and Humanized Mice after Carotid or Femoral Arterial Injury. |
| Q34429450 | Effects of exogenous recombinant APC in mouse models of ischemia reperfusion injury and of atherosclerosis |
| Q42713376 | Feeling the elephant of cardiovascular cell therapy |
| Q38083555 | Inflammation and immune system interactions in atherosclerosis |
| Q30849102 | Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation. |
| Q90521167 | MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS) |
| Q43182095 | New frontiers for platelet CD154. |
| Q26865593 | Noncoding RNAs regulate NF-κB signaling to modulate blood vessel inflammation |
| Q47645034 | Platelet CD40 Mediates Leukocyte Recruitment and Neointima Formation after Arterial Denudation Injury in Atherosclerosis-Prone Mice |
| Q30497499 | Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis |
| Q35656802 | Platelet PI3Kγ Contributes to Carotid Intima-Media Thickening under Severely Reduced Flow Conditions |
| Q38674677 | Platelet extracellular vesicles induce a pro-inflammatory smooth muscle cell phenotype. |
| Q34708937 | Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes |
| Q34795130 | Proinflammatory responses induced by CD40 in retinal endothelial and Müller cells are inhibited by blocking CD40-Traf2,3 or CD40-Traf6 signaling |
| Q38396097 | Regulation of atherosclerotic plaque inflammation |
| Q36000924 | Rosuvastatin Attenuates CD40L-Induced Downregulation of Extracellular Matrix Production in Human Aortic Smooth Muscle Cells via TRAF6-JNK-NF-κB Pathway |
| Q49369729 | Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. |
| Q90723624 | The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease |
| Q37829738 | The CD40-CD40L system in cardiovascular disease. |
| Q92983665 | The dual role of platelet-innate immune cell interactions in thrombo-inflammation |
| Q33937074 | The platelet as an immune cell-CD40 ligand and transfusion immunomodulation |
| Q26996707 | The role of costimulatory receptors of the tumour necrosis factor receptor family in atherosclerosis |
| Q42203442 | The role of platelets in the pathogenesis of systemic sclerosis |
| Q33996260 | Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans |
| Q34369244 | Tumor necrosis factor receptor-associated factor 1 (TRAF1) deficiency attenuates atherosclerosis in mice by impairing monocyte recruitment to the vessel wall |
| Q48161453 | Tumor necrosis factor receptor-associated factor 5 is an essential mediator of ischemic brain infarction. |
Search more.